Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial

Conclusions3-month sevelamer treatment did not reduce proteinuria in patients with CKD on maximal RAS blockade. Amelioration of inflammation and dyslipidemia with sevelamer treatment raises the possibility that it may confer benefit in patients with CKD beyond reduction of proteinuria.FundingSanofi (Milan, Italy).Trial RegistrationRegistered at ClinicalTrials.gov with study number NCT01968759.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research